αβ T细胞去除的异基因造血干细胞移植在成人血液肿瘤中的1/2期研究
多中心前瞻性单臂1/2期研究评估成人血液肿瘤患者接受αβ T细胞去除的异基因造血干细胞移植,主要终点为第100天急性GVHD发生率。
要点
- αβ T细胞去除移植后第100天2-4级aGVHD累积发生率为26%。
- 2年cGVHD累积发生率为23%,其中17%为中度。
- 2年复发累积发生率29%,非复发死亡率32%。
核心结论
- αβ T细胞去除的异基因造血干细胞移植后100天内仅26%患者发生2-4级aGVHD,且2年后cGVHD发生率低。
研究设计与样本
- 移植外周血干细胞来自匹配亲缘或不相关供者(10/10和9/10),主要终点为第100天aGVHD发生率。
- 预处理为抗胸腺细胞球蛋白、白消安和氟达拉滨,移植后28天霉酚酸,最短随访24个月。
主要发现
- 输注CD34+细胞中位数6.1×10^6/kg,αβ T细胞中位数16.3×10^3/kg。
- 第100天2-4级和3-4级aGVHD累积发生率分别为26%和14%。
- 54%受试者接受预防性供者淋巴细胞输注(1×10^5 CD3+ T细胞/kg),2年时2-4级和3-4级aGVHD累积发生率分别为37%和17%。
- 免疫监测显示NK和γδ T细胞早期重建,巨细胞病毒再激活与记忆样NK细胞扩增相关。
- 2年复发累积发生率29%,非复发死亡率32%,cGVHD累积发生率23%(中度17%)。
关键数值与推荐
- 第100天2-4级aGVHD累积发生率为26%,3-4级为14%。
- 2年cGVHD累积发生率为23%,其中中度占17%。
- 2年复发累积发生率为29%,非复发死亡率为32%。
临床怎么用
- αβ T细胞去除移植可作为降低aGVHD和cGVHD发生率的策略,需关注复发和非复发死亡风险。
- 预防性供者淋巴细胞输注后需监测aGVHD发生率升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a multicenter prospective single-arm phase 1/2 study that assesses the outcome of αβ T-cell depleted allogeneic hematopoietic stem cell transplantation (allo-HSCT) of peripheral blood derived stem cells from matched related, or unrelated donors (10/10 and 9/10) in adults, with the incidence of acute graft-versus-host disease (aGVHD) as the primary end point at day 100. Thirty-five adults (median age, 59; range, 19-69 years) were enrolled. Conditioning consisted of antithymocyte globulin, busulfan, and fludarabine, followed by 28 days of mycophenolic acid after allo-HSCT. The minimal follow-up time was 24 months. The median number of infused CD34+ cells and αβ T cells were 6.1 × 106 and 16.3 × 103 cells per kg, respectively. The cumulative incidence (CI) of aGVHD grades 2-4 and 3-4 at day 100 was 26% and 14%. One secondary graft failure was observed. A prophylactic donor lymphocyte infusion (DLI) (1 × 105 CD3+ T cells per kg) was administered to 54% of the subjects, resulting in a CI of aGVHD grades 2-4 and 3-4 to 37% and 17% at 2 years. Immune monitoring revealed an early reconstitution of natural killer (NK) and γδ T cells. Cytomegalovirus reactivation associated with expansion of memory-like NK cells. The CI of relapse was 29%, and the nonrelapse mortality 32% at 2 years. The 2-year CI of chronic GVHD (cGVHD) was 23%, of which 17% was moderate. We conclude that only 26% of patients developed aGVHD 2-4 after αβ T-cell-depleted allo-HSCT within 100 days and was associated with a low incidence of cGVHD after 2 years. This trial was registered at www.trialregister.nl as #NL4767.
引用
- de Witte MA, Janssen A, Nijssen K, et al. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Adv. 2021. PMID: 33570642. doi:10.1182/bloodadvances.2020002444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。